Cargando…

The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol

INTRODUCTION: Infantile hemangiomas (IH) are the most common benign vascular tumors of childhood, with an incidence of 5–10% during the first year of age. Propranolol is considered the first-line treatment for this condition. Potentially there is a high probability of negative results to therapy, be...

Descripción completa

Detalles Bibliográficos
Autores principales: Castaneda, Saul, Melendez-Lopez, Samuel, Garcia, Esbeydy, De la Cruz, Hermelinda, Sanchez-Palacio, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055552/
https://www.ncbi.nlm.nih.gov/pubmed/27461120
http://dx.doi.org/10.1007/s12325-016-0391-9
_version_ 1782458775744020480
author Castaneda, Saul
Melendez-Lopez, Samuel
Garcia, Esbeydy
De la Cruz, Hermelinda
Sanchez-Palacio, Jose
author_facet Castaneda, Saul
Melendez-Lopez, Samuel
Garcia, Esbeydy
De la Cruz, Hermelinda
Sanchez-Palacio, Jose
author_sort Castaneda, Saul
collection PubMed
description INTRODUCTION: Infantile hemangiomas (IH) are the most common benign vascular tumors of childhood, with an incidence of 5–10% during the first year of age. Propranolol is considered the first-line treatment for this condition. Potentially there is a high probability of negative results to therapy, because in many countries there are no treatment protocols or propranolol formulations appropriate for the pediatric population. The objective of the present study was to evaluate the impact of pharmacist interventions such as detecting, analyzing, and solving problems presented during treatment with propranolol in patients with IH. METHODS: An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol. Pharmacist participation consisted of development of an extemporaneous formulation and counseling the child’s parents. At each visit to the pharmacy service, family members were interviewed, detecting and classifying problems related to treatment. RESULTS: Sixty-three children with IH were treated during the period under review. Patient ages ranged from 3 to 11 months old; 64% were female and 36% were male. Forty-nine problems in 30 patients were detected, principally inadequate dose (18.4%), non-adherence to treatment (16.3%), side effects (14.3%), and wrong administration (14.3%). Of the problems detected, 81.6% were resolved. Interventions by the pharmacist in 27 patients were intensive counseling on adherence to therapy (20%), detection of adverse effects (11.4%), and adjustment of the dose (22.9%). In 95.2% of patients a good response to treatment was obtained compared with 77.2% reported in European studies without pharmacist intervention. CONCLUSION: It seems that pharmacist participation increases adherence to treatment and reduces the likelihood of adverse effects, allowing for safe and effective therapy in patients with IH.
format Online
Article
Text
id pubmed-5055552
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-50555522016-10-26 The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol Castaneda, Saul Melendez-Lopez, Samuel Garcia, Esbeydy De la Cruz, Hermelinda Sanchez-Palacio, Jose Adv Ther Brief Report INTRODUCTION: Infantile hemangiomas (IH) are the most common benign vascular tumors of childhood, with an incidence of 5–10% during the first year of age. Propranolol is considered the first-line treatment for this condition. Potentially there is a high probability of negative results to therapy, because in many countries there are no treatment protocols or propranolol formulations appropriate for the pediatric population. The objective of the present study was to evaluate the impact of pharmacist interventions such as detecting, analyzing, and solving problems presented during treatment with propranolol in patients with IH. METHODS: An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol. Pharmacist participation consisted of development of an extemporaneous formulation and counseling the child’s parents. At each visit to the pharmacy service, family members were interviewed, detecting and classifying problems related to treatment. RESULTS: Sixty-three children with IH were treated during the period under review. Patient ages ranged from 3 to 11 months old; 64% were female and 36% were male. Forty-nine problems in 30 patients were detected, principally inadequate dose (18.4%), non-adherence to treatment (16.3%), side effects (14.3%), and wrong administration (14.3%). Of the problems detected, 81.6% were resolved. Interventions by the pharmacist in 27 patients were intensive counseling on adherence to therapy (20%), detection of adverse effects (11.4%), and adjustment of the dose (22.9%). In 95.2% of patients a good response to treatment was obtained compared with 77.2% reported in European studies without pharmacist intervention. CONCLUSION: It seems that pharmacist participation increases adherence to treatment and reduces the likelihood of adverse effects, allowing for safe and effective therapy in patients with IH. Springer Healthcare 2016-07-26 2016 /pmc/articles/PMC5055552/ /pubmed/27461120 http://dx.doi.org/10.1007/s12325-016-0391-9 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Brief Report
Castaneda, Saul
Melendez-Lopez, Samuel
Garcia, Esbeydy
De la Cruz, Hermelinda
Sanchez-Palacio, Jose
The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol
title The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol
title_full The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol
title_fullStr The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol
title_full_unstemmed The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol
title_short The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol
title_sort role of the pharmacist in the treatment of patients with infantile hemangioma using propranolol
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055552/
https://www.ncbi.nlm.nih.gov/pubmed/27461120
http://dx.doi.org/10.1007/s12325-016-0391-9
work_keys_str_mv AT castanedasaul theroleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT melendezlopezsamuel theroleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT garciaesbeydy theroleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT delacruzhermelinda theroleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT sanchezpalaciojose theroleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT castanedasaul roleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT melendezlopezsamuel roleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT garciaesbeydy roleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT delacruzhermelinda roleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol
AT sanchezpalaciojose roleofthepharmacistinthetreatmentofpatientswithinfantilehemangiomausingpropranolol